Ventrus-Assembly Merger Brings Novel HBV Technology Public
Insights - Ventrus and Assembly Pharma plan to merge to develop their novel HBV te.chnology
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
The Retrophin Catch-22
Research - Retrophin management has pinned shareholders and potential investors between a rock and a hard spot, but there's reason to be optimistic.
PremiumFinally. An Encouraging Week in Biotech
Research - The sector-tracking iShares NASDAQ biotechnology ETF (IBB)Â took out some major levels of resistance in the Thursday trading session, catching the attention of traders in the … Continue Reading
Read now
FDA Kicks the Can Down the Road for Keryx’s Lead Drug
Insights - The FDA extended the approval decision date for Zerenex (ferric citrate) by 3 months, to September 7, following revisions to Keryx’s new drug application.
Read now
A Biotech ETF Broke Through Some Key Resistance
Insights - A key biotech ETF broke through some key resistance levels on Thursday, which is good for the sector. Can it overcome broader market concerns?
Read now
One Question to Ask When Considering Intercept Pharmaceuticals
Insights - Shares of Intercept Pharmaceuticals (ICPT) dropped early this week when documents attained through an FOIA request were made public, painting a picture of a management … Continue Reading
Read now
Antibiotic Incentives Loom, Cubist Still Positioned to Benefit
Research - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read now